Literature DB >> 10704891

Gastric pH profiles of beagle dogs and their use as an alternative to human testing.

M Akimoto1, N Nagahata, A Furuya, K Fukushima, S Higuchi, T Suwa.   

Abstract

Gastric pH levels were measured in samples of gastric aspirates from eight fasted beagle dogs. The gastric pH in fasting dogs fluctuated from 2.7 to 8.3, with a mean of 6.8+/-0.2 (SE). Each dog received the following four treatments in randomly-assigned order: (A) distilled water; (B) a placebo capsule; (C) pentagastrin, and (D) ranitidine. The gastric pH remained relatively constant after distilled water administration. In contrast, the treatments with pentagastrin and placebo capsule each lowered gastric pH. Pretreatment with pentagastrin was more successful in lowering gastric pH than that with placebo capsule. On the other hand, the pH rose above 7.0 in all dogs by the first hour after treatment with ranitidine. This animal model may be helpful in evaluating the biopharmaceutics of drugs exhibiting pH-dependent dissolution or decomposition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704891     DOI: 10.1016/s0939-6411(99)00070-3

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  18 in total

1.  Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Authors:  M N Martinez; B Mistry; V Lukacova; K A Lentz; J E Polli; S W Hoag; T Dowling; R Kona; R M Fahmy
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

2.  Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.

Authors:  Sherif I Farag Badawy; David B Gray; Fang Zhao; Duxin Sun; Alan E Schuster; Munir A Hussain
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

3.  Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.

Authors:  Binfeng Xia; Tycho Heimbach; Tsu-han Lin; Shoufeng Li; Hefei Zhang; Jennifer Sheng; Handan He
Journal:  AAPS PharmSciTech       Date:  2013-08-17       Impact factor: 3.246

4.  Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.

Authors:  Tycho Heimbach; Binfeng Xia; Tsu-han Lin; Handan He
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

5.  Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs.

Authors:  Eytan A Klausner; Eran Lavy; David Stepensky; Michael Friedman; Amnon Hoffman
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

6.  pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.

Authors:  Rong Zhou; Paul Moench; Christopher Heran; Xujin Lu; Neil Mathias; Teresa N Faria; Doris A Wall; Munir A Hussain; Ronald L Smith; Duxin Sun
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

7.  Exploration of intestinal calcium precipitation as a barrier to absorption at high calcium doses.

Authors:  Sandra Goss; Pauline Rafferty; Jennifer Prushko; Eric Gorman; Mitchell Taub; Robin Bogner
Journal:  Pharm Res       Date:  2008-06-17       Impact factor: 4.200

Review 8.  Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects.

Authors:  N Parrott; V Lukacova; G Fraczkiewicz; M B Bolger
Journal:  AAPS J       Date:  2009-01-29       Impact factor: 4.009

9.  In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness.

Authors:  Fiona McInnes; Nicola Clear; Michael Humphrey; Howard N E Stevens
Journal:  Pharm Res       Date:  2007-10-05       Impact factor: 4.200

Review 10.  Current methods for predicting human food effect.

Authors:  Kimberley A Lentz
Journal:  AAPS J       Date:  2008-05-24       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.